In China for China and the world

AstraZeneca regards nation as not just a sales market, but increasingly a major innovation hub

Global biopharmaceutical giant AstraZeneca PLC entered the Chinese mainland in 1993 and now has more than 10,000 employees across the country. AstraZeneca China has invested more than $1 billion in China and achieved sales of nearly $3.8 billion in 2018.

In an interview with China Daily, its chairman Leif Johansson talked about the company's development strategy in China, his views about the Chinese market, and how the Belt and Road Initiative benefits companies like AstraZeneca.